PROPHYLACTIC SUBCUTANEOUS MASTECTOMY IN HEREDITARY TRIPLE-NEGATIVE BREAST CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Breast cancer (BC) holds the lead in the structure of cancer incidence and mortality in women. This paper describes the authors’ experience in treating patients with a family history of breast cancer. About 80% of the BRCAl-associated breast tumors are known to have a triple-negative phenotype. In the Russian Federation, prophylactic subcutaneous mastectomy is carried out, as indicated, namely: BRCA1/2 mutations and a history of breast cancer. Combination therapy includes polychemotherapy (PCT) (Stage 1), surgery (Stage 2), and PCT (stage 3). Prophylactic subcutaneous mastectomy was first performed in patients with triple-negative breast cancer concurrent with BRCA1 mutation at the P.A. Herzen Moscow Oncology Research Institute.

Full Text

Restricted Access

About the authors

A. D ZIKIRYAKHODZHAEV

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia

Email: azizz@mail.ru
PhD, head of the Department of Oncology and reconstructive surgery of the mammary gland and skin 125284, Russia, Moscow, 2nd Botkinsky proezd 3

E. A RASSKAZOVA

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia

Email: rasskaz2@yandex.ru
PhD, a researcher at the Department of Oncology and reconstructive surgery of the mammary gland and skin 125284, Russia, Moscow, 2nd Botkinsky proezd 3

M. A FROLOVA

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Email: drfrolova@yandex.ru
PhD, Senior Research Assistant, Department of Clinical Pharmacology and Chemotherapy 115478, Russia, Moscow, Kashirskoye shosse 24

E. O IGNATOVA

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Email: md.ignatova@gmail.com
PhD student, Department of Clinical Pharmacology and Chemotherapy 115478, Russia, Moscow, Kashirskoye shosse 24

References

  1. Пономарева О.В. Современные представления о возможностях лекарственной терапии пациенток с тройным негативным раком молочной железы (ASKO 2011). Онкология. 2011; 13(3): 214-21
  2. Тюляндин С.А., Стенина М.Б., Фролова М.А. Тройной негативный рак молочной железы. Практическая онкология. 2010; 11(4): 247-52
  3. Dar-Esfahani S., Loibl S., Müller B.M., Roller M., Denkert C., Komor M. et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and her2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 2009; 11(5): R69.
  4. Torrisi R., Balduzzi A., Ghisini R., Rocca A., Bottiglieri L., Giovanardi F. et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother. Pharmacol. 2008; 62(4): 667-72

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies